Ovarian Cancer — Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
Citation(s)
An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND